Jazz Pharmaceuticals (JAZZ)
(Delayed Data from NSDQ)
$109.04 USD
-2.37 (-2.13%)
Updated Oct 1, 2024 04:00 PM ET
After-Market: $109.52 +0.48 (0.44%) 7:58 PM ET
2-Buy of 5 2
A Value C Growth D Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$109.04 USD
-2.37 (-2.13%)
Updated Oct 1, 2024 04:00 PM ET
After-Market: $109.52 +0.48 (0.44%) 7:58 PM ET
2-Buy of 5 2
A Value C Growth D Momentum A VGM
Zacks News
5 Excellent Value Stocks Based on Low PEG Ratio
by Zacks Equity Research
While P/E alone fails to identify a true value stock, PEG helps find the intrinsic value of a stock.
Enanta Pharmaceuticals (ENTA) Looks Good: Stock Adds 9.6% in Session
by Zacks Equity Research
Enanta Pharmaceuticals, Inc. (ENTA) was a big mover last session, as the company saw its shares rise over 9% on the day.
Ironwood Pharma's Combination Gout Drug Gets FDA Approval
by Zacks Equity Research
Ironwood Pharmaceuticals, Inc. (IRWD) announced that the FDA has approved Duzallo for the treatment of hyperuricemia in patients with uncontrolled gout.
Rally Set to Resume: Buy These 5 Value Picks on the Dip
by Swarup Gupta
Morgan Stanley believes that conditions for a Bull Run remain in place.
Jazz Pharmaceuticals Arm Announces $500M Senior Notes Offer
by Zacks Equity Research
Jazz Pharmaceuticals (JAZZ) announces private offering of exchangeable senior notes to qualified institutional buyers to raise proceeds and repay debt.
Endo International (ENDP) Jumps: Stock Rises 6.9%
by Zacks Equity Research
Endo International (ENDP) was a big mover last session, as the company saw its shares rise almost 7% on the day amid huge volumes.
Jounce Therapeutics (JNCE) Jumps: Stock Moves 7.4% Higher
by Zacks Equity Research
Jounce Therapeutics, Inc. (JNCE) moved big last session, as its shares jumped over 7% on the day.
Jazz Pharma (JAZZ) Q2 Earnings & Revenues Miss, View Intact
by Zacks Equity Research
Jazz Pharma's (JAZZ) earnings and revenues miss estimates. However, the top line rises year over year owing to higher sales of the company's marketed drug, Xyrem.
Can Jazz Pharma (JAZZ) Spring a Surprise in Q2 Earnings?
by Zacks Equity Research
Jazz Pharma's (JAZZ) lead drug, Xyrem, is likely to deliver a strong performance in Q2, thanks to label expansion efforts.
AVEO's Kidney Cancer Candidate Gets CHMP Recommendation
by Zacks Equity Research
AVEO Pharmaceuticals, Inc. (AVEO) announced on Friday that the Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of its lead candidate, Fotivda (tivozanib), for the treatment of advanced renal cell carcinoma (RCC).
Why Is Jazz Pharmaceuticals (JAZZ) Down 3.3% Since the Last Earnings Report?
by Zacks Equity Research
Jazz Pharmaceuticals (JAZZ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Jazz Pharma Sleep Disorder Candidate Positive in Phase III
by Zacks Equity Research
Jazz Pharmaceuticals plc (JAZZ) announced positive efficacy results from studies evaluating its lead pipeline candidate, JZP-110, in adult patients with excessive sleepiness (ES) associated with narcolepsy and obstructive sleep apnea (OSA).
Jazz Pharmaceuticals' Vyxeos NDA Granted Priority Review
by Zacks Equity Research
Jazz Pharmaceuticals plc (JAZZ) announced that the New Drug Application (NDA) for its experimental leukemia candidate Vyxeos has been accepted for priority review by the FDA.
BioLineRx Makes Regulatory Submission for Trial of BL-8040
by Zacks Equity Research
BioLineRx Ltd. (BLRX) announced that it has submitted a regulatory filing required to start a phase Ib study for BL-8040 in combination with Roche Group's (RHHBY) Tecentriq (atezolizumab).
Jazz Pharmaceuticals (JAZZ) Misses Q1 Earnings & Sales
by Zacks Equity Research
Jazz Pharmaceuticals Public Limited Company (JAZZ) reported first-quarter 2017 earnings of $1.41 per share, which narrowly missed the Zacks Consensus Estimate of $1.42.
Jazz Pharma (JAZZ) Q1 Earnings: Stock Likely to Disappoint?
by Zacks Equity Research
Jazz Pharmaceuticals plc (JAZZ) is scheduled to report first-quarter 2017 results on May 9, after the market closes.
Jazz Pharma Completes NDA Filing for Leukemia Drug to FDA
by Zacks Equity Research
Jazz Pharmaceuticals plc (JAZZ) recently announced that it has completed the rolling submission of a new drug application (NDA) to the FDA, seeking approval for its leukemia candidate, Vyxeos.
Jazz Pharma (JAZZ) Up 7.6% Since Earnings Report: Can It Continue?
by Zacks Equity Research
Jazz Pharma (JAZZ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Jazz Sleep Disorder Drug Positive in Phase III Studies
by Zacks Equity Research
Jazz Pharmaceuticals plc (JAZZ) recently announced positive efficacy results from two phase III studies evaluating the safety and efficacy of its lead pipeline candidate JZP-110 for the treatment of excessive sleepiness.
Jazz Initiates Phase III Study for Narcolepsy Candidate
by Zacks Equity Research
Jazz Pharmaceuticals plc (JAZZ) recently announced the initiation of patient enrollment in a phase III study evaluating the efficacy and safety of its pipeline candidate, JZP-258, for the potential treatment of adult narcolepsy patients.
Jazz Pharma (JAZZ) Q4 Earnings Beat, Sales Miss Estimates
by Zacks Equity Research
Jazz Pharmaceuticals Public Limited Company (JAZZ) reported fourth-quarter 2016 earnings of $1.91 per share which beat the Zacks Consensus Estimate of $1.65.
Jazz Pharma (JAZZ) Q4 Earnings: Is a Surprise in Store?
by Zacks Equity Research
Jazz Pharmaceuticals plc (JAZZ) is scheduled to report fourth-quarter 2016 results on Feb 28 after the market closes.
5 Drug Stocks Poised to Beat Earnings Estimates in Q4
by Arpita Dutt
Medical is one of the few sectors that has consistently recorded earnings growth over the last 4 quarters. Here is a look at 5 pharma and biotech stocks that look set to beat Q4 earnings estimates.
Can Jazz Pharmaceuticals Be a Top Choice for Value Investors?
by Zacks Equity Research
Value investing is easily one of the most popular ways to find great stocks in any market environment.
Can Jazz Pharmaceuticals Be a Top Choice for Value Investors?
by Zacks Equity Research
Let's see if Jazz Pharmaceuticals Public Limited Company (JAZZ) stock is a good choice for value-oriented investors right now from multiple angles.